Stifel lowered the firm’s price target on Astrana Health (ASTH) to $56 from $70 and keeps a Buy rating on the shares ahead of Astrana reporting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results